Reasons for Initiation and Discontinuation of Pharmacological Therapies of Osteoporosis in Veterans With Spinal Cord Injury and Disorder

Brian Le, Cara Ray, Beverly Gonzalez, Scott Miskevics, Frances M. Weaver, Michael Priebe, Laura D Carbone

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Medications for osteoporosis have not been reported to reduce fracture rates in patients with spinal cord injury and disorders (SCI/D), yet these medications are still prescribed. Clinical decision-making underscoring the initiation and discontinuation of osteoporosis medications in SCI/D remains poorly understood. Methodology: Veterans with a SCI/D with at least one prescription for an osteoporosis medication (bisphosphonate, calcitonin, denosumab, raloxifene, and teriparatide) who received healthcare within Veterans Affairs (VA) from 2005 to 2015 were identified using VA administrative databases. A 10% subsample of Veterans was selected for electronic health record review. Results: Two hundred and sixty-seven Veterans with 330 prescriptions underwent electronic health record review. Bisphosphonates were the most frequently prescribed medication for osteoporosis (n = 223, 67.6%). Of the 187 Veterans with prescriptions for prevention or treatment of osteoporosis, the primary reason for initiation was Dual Energy X-ray Absorptiometry (DXA) scan with osteopenia or osteoporosis (n = 119, 63.6% of Veterans), primarily at the hip (81.0% of DXAs). The majority (79.0%) of DXAs were “screening tests,” with SCI/D being the sole reason for the scan. Fractures (n = 51, 27.3%) and fall risk concerns (n = 29, 15.5%) were other major reasons for initiation. On average, oral bisphosphonates were filled for <3 yr, with medication-related side effects (n = 23, 15.8% of bisphosphonates discontinued), predominately gastrointestinal (n = 17, 73.9% of reported side effects), the most common reason for discontinuation. Drug holidays occurred in 14.3% of 35 oral bisphosphonates used for ≥5 yr. No cases of osteonecrosis of the jaw were found. There was one case of an atypical femoral fracture which could not be confirmed. Conclusions: The decision to initiate pharmacological therapies in SCI/D is primarily based on osteopenia or osteoporosis at the hip by screening DXAs. Gastrointestinal side effects are the major reason for discontinuation of oral bisphosphonates. New therapies for osteoporosis in SCI/D are needed.

Original languageEnglish (US)
JournalJournal of Clinical Densitometry
DOIs
StatePublished - Jan 1 2019

Fingerprint

Spinal Cord Diseases
Veterans
Spinal Cord Injuries
Osteoporosis
Diphosphonates
Pharmacology
Prescriptions
Metabolic Bone Diseases
Electronic Health Records
Therapeutics
Hip
Teriparatide
Holidays
Femoral Fractures
Osteonecrosis
Photon Absorptiometry
Calcitonin
Jaw
Databases
Delivery of Health Care

Keywords

  • Bisphosphonate
  • DXA
  • SCI/D
  • fracture
  • medications
  • osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Reasons for Initiation and Discontinuation of Pharmacological Therapies of Osteoporosis in Veterans With Spinal Cord Injury and Disorder. / Le, Brian; Ray, Cara; Gonzalez, Beverly; Miskevics, Scott; Weaver, Frances M.; Priebe, Michael; Carbone, Laura D.

In: Journal of Clinical Densitometry, 01.01.2019.

Research output: Contribution to journalArticle

@article{bae2ce98c02546ff9392a611c62034e8,
title = "Reasons for Initiation and Discontinuation of Pharmacological Therapies of Osteoporosis in Veterans With Spinal Cord Injury and Disorder",
abstract = "Introduction: Medications for osteoporosis have not been reported to reduce fracture rates in patients with spinal cord injury and disorders (SCI/D), yet these medications are still prescribed. Clinical decision-making underscoring the initiation and discontinuation of osteoporosis medications in SCI/D remains poorly understood. Methodology: Veterans with a SCI/D with at least one prescription for an osteoporosis medication (bisphosphonate, calcitonin, denosumab, raloxifene, and teriparatide) who received healthcare within Veterans Affairs (VA) from 2005 to 2015 were identified using VA administrative databases. A 10{\%} subsample of Veterans was selected for electronic health record review. Results: Two hundred and sixty-seven Veterans with 330 prescriptions underwent electronic health record review. Bisphosphonates were the most frequently prescribed medication for osteoporosis (n = 223, 67.6{\%}). Of the 187 Veterans with prescriptions for prevention or treatment of osteoporosis, the primary reason for initiation was Dual Energy X-ray Absorptiometry (DXA) scan with osteopenia or osteoporosis (n = 119, 63.6{\%} of Veterans), primarily at the hip (81.0{\%} of DXAs). The majority (79.0{\%}) of DXAs were “screening tests,” with SCI/D being the sole reason for the scan. Fractures (n = 51, 27.3{\%}) and fall risk concerns (n = 29, 15.5{\%}) were other major reasons for initiation. On average, oral bisphosphonates were filled for <3 yr, with medication-related side effects (n = 23, 15.8{\%} of bisphosphonates discontinued), predominately gastrointestinal (n = 17, 73.9{\%} of reported side effects), the most common reason for discontinuation. Drug holidays occurred in 14.3{\%} of 35 oral bisphosphonates used for ≥5 yr. No cases of osteonecrosis of the jaw were found. There was one case of an atypical femoral fracture which could not be confirmed. Conclusions: The decision to initiate pharmacological therapies in SCI/D is primarily based on osteopenia or osteoporosis at the hip by screening DXAs. Gastrointestinal side effects are the major reason for discontinuation of oral bisphosphonates. New therapies for osteoporosis in SCI/D are needed.",
keywords = "Bisphosphonate, DXA, SCI/D, fracture, medications, osteoporosis",
author = "Brian Le and Cara Ray and Beverly Gonzalez and Scott Miskevics and Weaver, {Frances M.} and Michael Priebe and Carbone, {Laura D}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jocd.2019.06.003",
language = "English (US)",
journal = "Journal of Clinical Densitometry",
issn = "1094-6950",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Reasons for Initiation and Discontinuation of Pharmacological Therapies of Osteoporosis in Veterans With Spinal Cord Injury and Disorder

AU - Le, Brian

AU - Ray, Cara

AU - Gonzalez, Beverly

AU - Miskevics, Scott

AU - Weaver, Frances M.

AU - Priebe, Michael

AU - Carbone, Laura D

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Medications for osteoporosis have not been reported to reduce fracture rates in patients with spinal cord injury and disorders (SCI/D), yet these medications are still prescribed. Clinical decision-making underscoring the initiation and discontinuation of osteoporosis medications in SCI/D remains poorly understood. Methodology: Veterans with a SCI/D with at least one prescription for an osteoporosis medication (bisphosphonate, calcitonin, denosumab, raloxifene, and teriparatide) who received healthcare within Veterans Affairs (VA) from 2005 to 2015 were identified using VA administrative databases. A 10% subsample of Veterans was selected for electronic health record review. Results: Two hundred and sixty-seven Veterans with 330 prescriptions underwent electronic health record review. Bisphosphonates were the most frequently prescribed medication for osteoporosis (n = 223, 67.6%). Of the 187 Veterans with prescriptions for prevention or treatment of osteoporosis, the primary reason for initiation was Dual Energy X-ray Absorptiometry (DXA) scan with osteopenia or osteoporosis (n = 119, 63.6% of Veterans), primarily at the hip (81.0% of DXAs). The majority (79.0%) of DXAs were “screening tests,” with SCI/D being the sole reason for the scan. Fractures (n = 51, 27.3%) and fall risk concerns (n = 29, 15.5%) were other major reasons for initiation. On average, oral bisphosphonates were filled for <3 yr, with medication-related side effects (n = 23, 15.8% of bisphosphonates discontinued), predominately gastrointestinal (n = 17, 73.9% of reported side effects), the most common reason for discontinuation. Drug holidays occurred in 14.3% of 35 oral bisphosphonates used for ≥5 yr. No cases of osteonecrosis of the jaw were found. There was one case of an atypical femoral fracture which could not be confirmed. Conclusions: The decision to initiate pharmacological therapies in SCI/D is primarily based on osteopenia or osteoporosis at the hip by screening DXAs. Gastrointestinal side effects are the major reason for discontinuation of oral bisphosphonates. New therapies for osteoporosis in SCI/D are needed.

AB - Introduction: Medications for osteoporosis have not been reported to reduce fracture rates in patients with spinal cord injury and disorders (SCI/D), yet these medications are still prescribed. Clinical decision-making underscoring the initiation and discontinuation of osteoporosis medications in SCI/D remains poorly understood. Methodology: Veterans with a SCI/D with at least one prescription for an osteoporosis medication (bisphosphonate, calcitonin, denosumab, raloxifene, and teriparatide) who received healthcare within Veterans Affairs (VA) from 2005 to 2015 were identified using VA administrative databases. A 10% subsample of Veterans was selected for electronic health record review. Results: Two hundred and sixty-seven Veterans with 330 prescriptions underwent electronic health record review. Bisphosphonates were the most frequently prescribed medication for osteoporosis (n = 223, 67.6%). Of the 187 Veterans with prescriptions for prevention or treatment of osteoporosis, the primary reason for initiation was Dual Energy X-ray Absorptiometry (DXA) scan with osteopenia or osteoporosis (n = 119, 63.6% of Veterans), primarily at the hip (81.0% of DXAs). The majority (79.0%) of DXAs were “screening tests,” with SCI/D being the sole reason for the scan. Fractures (n = 51, 27.3%) and fall risk concerns (n = 29, 15.5%) were other major reasons for initiation. On average, oral bisphosphonates were filled for <3 yr, with medication-related side effects (n = 23, 15.8% of bisphosphonates discontinued), predominately gastrointestinal (n = 17, 73.9% of reported side effects), the most common reason for discontinuation. Drug holidays occurred in 14.3% of 35 oral bisphosphonates used for ≥5 yr. No cases of osteonecrosis of the jaw were found. There was one case of an atypical femoral fracture which could not be confirmed. Conclusions: The decision to initiate pharmacological therapies in SCI/D is primarily based on osteopenia or osteoporosis at the hip by screening DXAs. Gastrointestinal side effects are the major reason for discontinuation of oral bisphosphonates. New therapies for osteoporosis in SCI/D are needed.

KW - Bisphosphonate

KW - DXA

KW - SCI/D

KW - fracture

KW - medications

KW - osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=85067929668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067929668&partnerID=8YFLogxK

U2 - 10.1016/j.jocd.2019.06.003

DO - 10.1016/j.jocd.2019.06.003

M3 - Article

AN - SCOPUS:85067929668

JO - Journal of Clinical Densitometry

JF - Journal of Clinical Densitometry

SN - 1094-6950

ER -